|A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care||
||358||All||18 Years and older (Adult, Senior)||NCT00071799||AZA PH GL 2003 CL 001||November 2003||July 2007||July 2007||November 5, 2003||August 31, 2010||July 5, 2010||
|2||NCT01869114||Recruiting||Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy||
||83||All||18 Years and older (Adult, Senior)||NCT01869114||12D.587
|July 8, 2013||July 8, 2018||January 2020||June 5, 2013||December 6, 2017||
† Study has passed its completion date and status has not been verified in more than two years.